The Latin America, Middle East and Africa Gastroesophageal Reflux Disease Therapeutics Market would witness market growth of 5.1% CAGR during the forecast period (2022-2028).
Acid contact with the esophageal mucosa still plays a significant role in developing symptoms and the induction of inflammatory lesions at the distal part of the esophagus. Hence, it is not unexpected that the primary medical strategy for treating GERD patients focuses on reducing acid output.
Because they bind to the H+K+ ATP-ase, which is the last step in the production of acid by the gastric parietal cell, proton pump inhibitors (PPIs) are the most potent antisecretory medications currently on the market. As a result, they have quickly replaced the less potent H2-receptor antagonists (H2RAs) as the first-choice medications for controlling this important element in the pathogenesis of GERD. PPIs have more antisecretory action than H2RAs, although their effectiveness varies depending on how much the clinical signs and symptoms of the condition are caused by acid.
The EE type of GERD is one of the most responsive, especially when it manifests with more severe mucosal damage, which falls between B and D of the well-known Los Angeles classification. Several randomized clinical studies, systematic reviews, and meta-analyses have shown that PPIs have a very high healing rate in these individuals. When PPIs are compared to placebo and H2RAs, their efficiency in treating esophageal mucosal changes is linked with a speedy remission of typical illness symptoms, notably heartburn.
In Israel, the proportion of adults and kids who are overweight or obese has increased. According to the KAP study from 2008, obesity affects 13.7%, and overweight affects 34% of adults over 18. An imbalance between the number of calories ingested and the energy lost during physical exercise leads to weight increase and, ultimately, obesity. Excess calories are typically consumed through high-calorie fast food, expanding portion sizes, and the low cost of high-calorie food. At the same time, physical activity has decreased due to the increased time people spend watching television, using computers, and using other electronic devices. The increasing obesity for various reasons is expected to surge the number of patients with digestive tract complications and boost the market's expansion in the region in LAMEA.
The Brazil market dominated the LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $99 Million by 2028. The Argentina market is experiencing a CAGR of 5.7% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 4.8% during (2022 - 2028).
Based on Type, the market is segmented into Antacids, Proton Pump Inhibitors (PPIs), H2 Receptor Blockers, and Pro-kinetic Agents. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide Gastroesophageal Reflux Disease Therapeutics Market is Projected to reach USD 5.6 Billion by 2028, at a CAGR of 2.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Eisai Co., Ltd., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Medigus Ltd., Sebela Pharmaceuticals, Phathom Pharmaceuticals, Inc., and Camber Pharmaceuticals, Inc. (Hetero Labs Limited).
Scope of the Study
Market Segments Covered in the Report:
By Type
- Antacids
- Proton Pump Inhibitors (PPIs)
- H2 Receptor Blockers
- Pro-kinetic Agents
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- AstraZeneca PLC
- Eisai Co., Ltd.
- GlaxoSmithKline PLC
- Takeda Pharmaceutical Company Limited
- Ironwood Pharmaceuticals, Inc.
- Johnson & Johnson
- Medigus Ltd.
- Sebela Pharmaceuticals
- Phathom Pharmaceuticals, Inc.
- Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Gastroesophageal Reflux Disease Therapeutics Market, by Type
1.4.2 LAMEA Gastroesophageal Reflux Disease Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type
3.1 LAMEA Antacids Market by Country
3.2 LAMEA Proton Pump Inhibitors (PPIs) Market by Country
3.3 LAMEA H2 Receptor Blockers Market by Country
3.4 LAMEA Pro-kinetic Agents Market by Country
Chapter 4. LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Country
4.1 Brazil Gastroesophageal Reflux Disease Therapeutics Market
4.1.1 Brazil Gastroesophageal Reflux Disease Therapeutics Market by Type
4.2 Argentina Gastroesophageal Reflux Disease Therapeutics Market
4.2.1 Argentina Gastroesophageal Reflux Disease Therapeutics Market by Type
4.3 UAE Gastroesophageal Reflux Disease Therapeutics Market
4.3.1 UAE Gastroesophageal Reflux Disease Therapeutics Market by Type
4.4 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market
4.4.1 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market by Type
4.5 South Africa Gastroesophageal Reflux Disease Therapeutics Market
4.5.1 South Africa Gastroesophageal Reflux Disease Therapeutics Market by Type
4.6 Nigeria Gastroesophageal Reflux Disease Therapeutics Market
4.6.1 Nigeria Gastroesophageal Reflux Disease Therapeutics Market by Type
4.7 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market
4.7.1 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type
Chapter 5. Company Profiles
5.1 Takeda Pharmaceutical Company Limited
5.1.1 Company Overview
5.1.2 Financial Analysis
5.1.3 Regional Analysis
5.1.4 Research & Development Expense
5.2 AstraZeneca PLC
5.2.1 Company Overview
5.2.2 Financial Analysis
5.2.3 Regional Analysis
5.2.4 Research & Development Expenses
5.3 GlaxoSmithKline PLC (GSK)
5.3.1 Company Overview
5.3.2 Financial Analysis
5.3.3 Segmental and Regional Analysis
5.3.4 Research & Development Expense
5.4 Johnson & Johnson
5.4.1 Company Overview
5.4.2 Financial Analysis
5.4.3 Segmental &Regional Analysis
5.4.4 Research & Development Expenses
5.5 Ironwood Pharmaceuticals, Inc.
5.5.1 Company Overview
5.5.2 Financial Analysis
5.5.3 Regional Analysis
5.5.4 Research & Development Expenses
5.6 Eisai Co., Ltd.
5.6.1 Company Overview
5.6.2 Financial Analysis
5.6.3 Segmental and Regional Analysis
5.6.4 Research & Development Expenses
5.7 Medigus Ltd.
5.7.1 Company Overview
5.7.2 Financial Analysis
5.7.3 Segmental and Regional Analysis
5.7.4 Research & Development Expenses
5.8 Sebela Pharmaceuticals
5.8.1 Company Overview
5.8.2 Recent strategies and developments:
5.8.2.1 Partnerships, Collaborations, and Agreements:
5.9 Phathom Pharmaceuticals, Inc.
5.9.1 Company Overview
5.9.2 Research & Development Expenses
5.9.3 Recent strategies and developments:
5.9.3.1 Partnerships, Collaborations, and Agreements:
5.10. Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
5.10.1 Company Overview
5.10.2 Recent strategies and developments:
5.10.2.1 Product Launches and Product Expansions:
TABLE 1 LAMEA Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 2 LAMEA Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 3 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 4 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 5 LAMEA Antacids Market by Country, 2018 - 2021, USD Million
TABLE 6 LAMEA Antacids Market by Country, 2022 - 2028, USD Million
TABLE 7 LAMEA Proton Pump Inhibitors (PPIs) Market by Country, 2018 - 2021, USD Million
TABLE 8 LAMEA Proton Pump Inhibitors (PPIs) Market by Country, 2022 - 2028, USD Million
TABLE 9 LAMEA H2 Receptor Blockers Market by Country, 2018 - 2021, USD Million
TABLE 10 LAMEA H2 Receptor Blockers Market by Country, 2022 - 2028, USD Million
TABLE 11 LAMEA Pro-kinetic Agents Market by Country, 2018 - 2021, USD Million
TABLE 12 LAMEA Pro-kinetic Agents Market by Country, 2022 - 2028, USD Million
TABLE 13 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Country, 2018 - 2021, USD Million
TABLE 14 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Country, 2022 - 2028, USD Million
TABLE 15 Brazil Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 16 Brazil Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 17 Brazil Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 18 Brazil Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 19 Argentina Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 20 Argentina Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 21 Argentina Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 22 Argentina Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 23 UAE Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 24 UAE Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 25 UAE Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 26 UAE Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 27 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 28 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 29 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 30 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 31 South Africa Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 32 South Africa Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 33 South Africa Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 34 South Africa Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 35 Nigeria Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 36 Nigeria Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 37 Nigeria Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 38 Nigeria Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 39 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 40 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 41 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 42 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 43 Key Information – Takeda Pharmaceutical Company Limited
TABLE 44 KEY INFORMATION – AstraZeneca PLC
TABLE 45 Key Information – GlaxoSmithKline PLC
TABLE 46 Key information –Johnson & Johnson
TABLE 47 Key Information – Ironwood Pharmaceuticals, Inc.
TABLE 48 Key Information – Eisai Co., Ltd.
TABLE 49 Key Information – Medigus Ltd.
TABLE 50 Key Information – Sebela Pharmaceuticals
TABLE 51 Key Information – Phathom Pharmaceuticals, Inc.
TABLE 52 Key Information – Camber Pharmaceuticals, Inc.
List of Figures
FIG 1 Methodology for the research